|  |
| --- |
| **Supplemental Table 1. Adverse outcomes assessed.** |
| Outcome | Risk Interval (days)a | Comparison intervala | Clear period requiredb | ICD9 codes |
| Primary outcomes |  |  |  |  |
|  | Acute inpatient asthma stay or Emergency Dept. asthma encounterc | 1 to 14 | 29 to 42 | None | 493.xx |
|  | Outpatient asthma visit | 1 to 14 | 29 to 42 | None | 493.xx |
| Secondary outcomesd |  |  |  |  |
|  | Afebrile seizures/ nonspecific paroxysmal spell | 1 to 7 | 29 to 42 | 60 days | 780.3, 780.39 |
|  | Bell's palsy | 1 to 14 | 29 to 42 | 60 days | 351.0x |
|  | Febrile seizure | 0 to ≤2 | 29 to 42 | 60 days | 780.31, 780.32 |
|  | Epistaxis | 1 to 7 | 29 to 42 | 60 days | 784.7x |
|  | Fever | 1 to ≤2 | 29 to 42 | 60 days | 780.6x |
|  | Gastrointestinal disorders | 1 to 7 | 29 to 42 | 60 days | 003.0x, 008.45, 008.8x, 009.0x, 009.1x, 009.2x, 009.3x, 488.19, 488.89, 558.9x, 564.1x, 564.5x, 787.01,787.91 |
|  | Migraine | 1 to 7 | 29 to 42 | 60 days | 346.xx |
|  | Otitis media | 1 to 7 | 29 to 42 | 60 days | 381.xx |
|  | Sinusitis | 1 to 7 | 29 to 42 | 60 days | 461.xx, 461.0x, 461.1x, 461.2x, 461.3x, 461.8x, 461.9x |
|   | Any non-asthma outpatient visite | 1 to 14 | 29 to 42 | None | na |
| a Intervals refer to the number of days after immunization with LAIV or IIV. In all models, events were counted only if they occurred during the risk or comparison interval. LAIV: live attenuated influenza vaccine; IIV: inactivated influenza vaccine. |
| b Event was only counted if there was not another event of the same kind in the prior (x) days, where "x" is the clear period required.  |
| c Sensitivity analyses were also run using an alternative risk interval (7 to <=28 days) and comparison interval (29 to <=50 days).  |
| d For all these events except "any non-asthma outpatient visit" diagnosis could be in any setting.  |
| e Non-asthma visits were not considered to be adverse outcomes, but were assessed as a negative control, since we did not expect the differences between IIV and LAIV with respect to these visits.  |

|  |
| --- |
| **Supplemental Table 2. Summary of chart review results.**  |
|  | IIV |  | LAIV |
|  |   |   | Asthma Type |
| Characteristic | Remote history of asthma only |   | Active, persistent | Active, not persistent  | Remote history of asthma only | All asthma types |
| Number of immunizations |  82,198  |  |  14,039  |  16,160  |  26,627  |  56,826  |
| Number of outpatient adverse events prior to chart review confirmation |  |  |  |  |  |  |
|  1 to 14 days after immunization | 300 |  | 201 | 120 | 40 |  361  |
|  29 to 42 days after immunization | 272 |  | 273 | 145 | 67 |  485  |
| Number of CONFIRMED outpatient adverse events by chart review |  |  |  |  |  |  |
|  1 to 14 days after immunization | 211 |  | 129 | 83 | 30 |  242  |
|  29 to 42 days after immunization | 192 |  | 187 | 112 | 50 |  349  |
| Percent of events confirmed |  |  |  |  |  |  |
|  1 to 14 days after immunization | *70%* |  | *64%* | *69%* | *75%* | *67%* |
|  29 to 42 days after immunization | *71%* |  | *68%* | *77%* | *75%* | *72%* |
|  All days in the two intervals | *70%* |  | *67%* | *74%* | *75%* | *70%* |